Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04175431 · ClinicalTrials.gov registry record · Phase 2
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
A Phase 2 study of Prostate Adenocarcinoma, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT04175431 is a Phase 2 study of Prostate Adenocarcinoma that is actively recruiting participants, run by University of Washington. The registered enrollment target is 100 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (54% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04175431, a Phase 2 study of Prostate Adenocarcinoma, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- RADIATION Radiation Therapy
- DRUG Prednisone
- DRUG Abiraterone Acetate
- PROCEDURE Lymphadenectomy
Study Locations (2)
Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2033-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04175431
The ClinicalTrials.gov registry entry for NCT04175431 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (54% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Positron Emission Tomography is the first listed.
NCT04175431 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Washington.
Frequently Asked Questions
What is clinical trial NCT04175431 about?
NCT04175431 is a clinical study titled "Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study". This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help...
What is the current status of trial NCT04175431?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-09-30. Estimated completion is 2033-07-01.
What conditions does trial NCT04175431 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT04175431?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Radiation Therapy (RADIATION), Prednisone (DRUG), Abiraterone Acetate (DRUG), Lymphadenectomy (PROCEDURE).
Who is sponsoring clinical trial NCT04175431?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04175431 being conducted?
This trial has 2 study locations across Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.